2seventy bio, Inc.
TSVT
$4.81
$0.061.26%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -75.12% | -70.12% | -80.98% | -10.25% | 167.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -75.12% | -70.12% | -80.98% | -10.25% | 167.38% |
| Cost of Revenue | -69.82% | -33.24% | -15.89% | -9.40% | -11.76% |
| Gross Profit | 63.10% | -16.41% | -416.31% | 9.17% | 52.28% |
| SG&A Expenses | -49.42% | -38.90% | -13.37% | -33.69% | 12.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -65.09% | -34.50% | -15.33% | -15.23% | -7.07% |
| Operating Income | 57.54% | 5.78% | -120.47% | 16.21% | 37.65% |
| Income Before Tax | 159.11% | -12.02% | -145.53% | -5.54% | 45.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 159.11% | -12.02% | -145.53% | -5.54% | 45.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 159.11% | -12.02% | -145.53% | -5.54% | 45.64% |
| EBIT | 57.54% | 5.78% | -120.47% | 16.21% | 37.65% |
| EBITDA | 59.12% | 5.75% | -128.91% | 17.38% | 37.90% |
| EPS Basic | 157.73% | 6.48% | -84.84% | 20.46% | 59.06% |
| Normalized Basic EPS | 61.90% | 19.72% | -85.07% | 43.42% | 59.07% |
| EPS Diluted | 154.22% | 6.48% | -84.84% | 20.46% | 58.85% |
| Normalized Diluted EPS | 63.86% | 19.72% | -85.07% | 43.42% | 59.07% |
| Average Basic Shares Outstanding | 2.39% | 19.79% | 32.84% | 32.68% | 32.79% |
| Average Diluted Shares Outstanding | 7.94% | 19.79% | 32.84% | 32.68% | 32.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
